Applied dna biotherapeutics subsidiary linearx to present data showcasing advantages of its enzymatically produced lineardna as substitute for plasmid dna in ivt mrna production at the 2nd annual mrna-based therapeutics summit

Stony brook, n.y.--(business wire)---- $apdn #lineardna--applied dna sciences, inc. (nasdaq: apdn) (the “company”), a leader in pcr-based technologies, today announced that dr. james a. hayward, president and ceo of applied dna and its majority-owned biotherapeutics subsidiary, linearx inc., will present data highlighting the advantages of its enzymatically produced lineardna (lindna) as an ivt template for mrna production at the 2nd annual mrna-based therapeutics summit on july 26-28, 2022, in boston, massachusett
APDN Ratings Summary
APDN Quant Ranking